Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Laryngoscope. 2017 Sep 20;128(2):E59–E67. doi: 10.1002/lary.26893

Fig. 1.

Fig. 1

DON inhibits the hyperproliferative behavior of iLTS scar fibroblasts seen in (A). Representative Masson's Trichrome Stain (Sigma Aldrich, St. Louis, Missouri, U.S.A.) of untreated iLTS scar fibroblasts, which contrasts with (B). Masson's trichrome stain of iLTS scar fibroblasts treated with DON. (C) Results of DON treatment on proliferation rate of iLTS scar fibroblasts, compared to untreated iLTS scar fibroblasts. DON-treated iLTS scar fibroblast proliferation rate does not significantly differ from the proliferation rate of normal fibroblasts. DON = 6-diazo-5-oxo-l-norleucine; iLTS = iatrogenic laryngotracheal stenosis. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]